Sognef was founded in 2018 to address the overlooked necessity for more accessible and comprehensive early diagnostics. Its vision is to offer a single liquid biopsy-based test that provides early stage diagnostics for cancers, cardiovascular, neurodegenerative, infectious, and rare diseases in a consolidated, cost-effective, simple, and practical manner. In the next three to five years, Sognef aims to develop diagnostic profiles or indications for all target diseases, with the goal of providing a single affordable, simple, and accurate blood test for a range of diseases. The startup also aims to detect diseases in their earliest stages for individuals regularly taking tests.
Sognef operates in the Biotechnology and Health Care industries, positioning itself at the intersection of cutting-edge technology and life-saving healthcare solutions. The lack of specific details about the headquarters and the last investment indicates potential opportunities for partnership and investment. As the startup progresses in realizing its ambitious vision, it presents an attractive opportunity for venture capital firms seeking to invest in innovative healthcare solutions.
